Lucid Diagnostics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Lishan Aklog
- Full Time Employees
- 82
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 360 Madison Avenue New York City NY United States of America 10017
- IPO Date
- Oct 14, 2021
- CIK
- 0001799011
- Website
- luciddx.com
- Similar Companies
- Business
- Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage cancer prevention medical diagnostics company focused on early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD). The company offers EsoGuard Esophageal DNA Test, a laboratory developed test (LDT) that detects esophageal precancer using next-generation sequencing on samples collected via the EsoCheck Esophageal Cell Collection Device, a 510(k)-cleared, non-invasive capsule-based tool for in-office esophageal cell collection; it operates LucidDx Labs Inc., a CLIA-certified, CAP-accredited clinical laboratory licensed by the New York State Department of Health. A subsidiary of PAVmed Inc. (Nasdaq: PAVM), Lucid Diagnostics targets at-risk populations including GERD patients and high-risk groups such as firefighters, with U.S.-focused commercialization supported by partnerships with healthcare networks, fire departments, and municipalities for screening programs. Founded in 2018 and headquartered at 360 Madison Avenue, 25th Floor, New York, New York, the company maintains a workforce of approximately 72 employees. Recent developments include a September 2025 public offering of common stock led by Canaccord Genuity as joint bookrunner to strengthen its balance sheet; a partnership with Hoag health system to launch a comprehensive EsoGuard testing program across digestive health, primary care, and concierge medicine; expansion into three new states projecting up to 15% revenue growth; publication of an NCI-sponsored study in the American Journal of Gastroenterology demonstrating EsoGuard's efficacy in non-symptomatic patients, potentially expanding the addressable market by 70%; and progress toward Medicare reimbursement including a Multi-X Contractor Advisory Committee meeting and final payment determination for EsoGuard.
Company News
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics Q2 Earnings Call Highlights
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics to Participate in Upcoming Investor Conferences
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Lucid Diagnostics: Positioned For A Medicare-Driven Inflection
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026